Calcium Phosphate Nanoparticle-Based Vaccines as a Platform for Improvement of HIV-1 Env Antibody Responses by Intrastructural Help by Damm, Dominik et al.
nanomaterials
Article
Calcium Phosphate Nanoparticle-Based Vaccines as a
Platform for Improvement of HIV-1 Env Antibody
Responses by Intrastructural Help
Dominik Damm 1, Leonardo Rojas-Sánchez 2, Hannah Theobald 1, Viktoriya Sokolova 2,
Richard T. Wyatt 3, Klaus Überla 1, Matthias Epple 2 and Vladimir Temchura 1,*
1 Institute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg,
91054 Erlangen, Germany; dominik.damm@uk-erlangen.de (D.D.); hannah.theobald@fau.de (H.T.);
klaus.ueberla@fau.de (K.Ü.)
2 Inorganic Chemistry and Center for Nanointegration Duisburg-Essen (CeNIDE), University of
Duisburg-Essen, 45141 Essen, Germany; leonardo.rojas-sanchez@uni-due.de (L.R.-S.);
viktoriya.sokolova@uni-due.de (V.S.); matthias.epple@uni-due.de (M.E.)
3 Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA;
wyatt@scripps.edu
* Correspondence: vladimir.temchura@fau.de; Tel.: +49-9131-85-43652
Received: 5 September 2019; Accepted: 25 September 2019; Published: 27 September 2019 
Abstract: Incorporation of immunodominant T-helper epitopes of licensed vaccines into virus-like
particles (VLP) allows to harness T-helper cells induced by the licensed vaccines to provide
intrastructural help (ISH) for B-cell responses against the surface proteins of the VLPs. To explore
whether ISH could also improve antibody responses to calcium phosphate (CaP) nanoparticle
vaccines we loaded the nanoparticle core with a universal T-helper epitope of Tetanus toxoid (p30)
and functionalized the surface of CaP nanoparticles with stabilized trimers of the HIV-1 envelope
(Env) resulting in Env-CaP-p30 nanoparticles. In contrast to soluble Env trimers, Env containing CaP
nanoparticles induced activation of naïve Env-specific B-cells in vitro. Mice previously vaccinated
against Tetanus raised stronger humoral immune responses against Env after immunization with
Env-CaP-p30 than mice not vaccinated against Tetanus. The enhancing effect of ISH on anti-Env
antibody levels was not attended with increased Env-specific IFN-γ CD4 T-cell responses that
otherwise may potentially influence the susceptibility to HIV-1 infection. Thus, CaP nanoparticles
functionalized with stabilized HIV-1 Env trimers and heterologous T-helper epitopes are able to
recruit heterologous T-helper cells induced by a licensed vaccine and improve anti-Env antibody
responses by intrastructural help.
Keywords: nano-vaccines; HIV-1 Env trimers; B-cell targeting; intrastructural help
1. Introduction
The unique characteristic of HIV-1 to infect activated CD4 T-cells requires alternative vaccination
strategies that differ from the classical approaches used [1]. Polyfunctional serum antibodies against
envelope glycoprotein (Env) of HIV-1 correlate with spontaneous HIV-1 control by elite controllers [2]
and appear to be crucial for vaccine-mediated protection against HIV-1 [3–5]. However, limited
breadth, poor persistence of antibody responses to Env, and potential enhancement of susceptibility to
HIV infection by vaccine-induced HIV-specific T-helper cell responses compromise HIV-1 vaccines
previously designed for clinical trials [6,7]. Recently we demonstrated how T-helper cells induced by a
licensed vaccine against Tetanus toxoid (TT) can be harnessed to provide help for Env-specific B-cells
in mice immunized with HIV-1 virus-like particles (VLP) containing T-helper epitopes of TT [8]. This
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“intrastructural help” [9] (ISH) can be explained by uptake of entire VLPs by Env-specific B-cells and
subsequent presentation of epitopes from all proteins of the VLPs on their major histocompatibility
complex class II (MHC-II) molecules to harness corresponding T-cell help [8,10].
Biodegradable calcium phosphate (CaP) nanoparticles have several advantages compared to
biological and polymer-based nanoparticles and have been used for experimental vaccination during the
past decade [11]. Previously we designed CaP nanoparticles covered with a model antigen in order to
achieve efficient targeting and activation of cognate B-cells in vitro [12] as well as induction of humoral
immune responses in vivo [13]. In animal models, where CD4 T-cells were genetically non-reactive to
the surface antigen of the CaP nanoparticles, incorporation of the p30 peptide, a promiscuous (universal)
T-helper epitope from TT [14], overcame the lack of functionally active CD4 T-cell epitopes [13]. These
data indicate that CaP nanoparticle-based vaccines might be potentially used for improvement of
HIV-Env antibody responses by the ISH approach.
A gp160 precursor of HIV-1 Env is proteolytically cleaved into non-covalently linked gp120 and
gp41 subunits, which assemble into a trimer of heterodimers [15]. Historically, the initial candidate
vaccines for immunization with Env-based antigens used monomeric gp120 [16]. Recent advances
in design and manufacturing of soluble HIV-1 Env trimers stabilized in the closed pre-fusion state
provide an antigenic form of Env that induces Env antibodies recognizing the quaternary conformation
associated with neutralizing activity against autologous HIV-1 [15,16].
In this study, we therefore designed CaP nanoparticles with stabilized HIV-1 Env trimers coupled
to the surface and universal T-helper peptides of TT in the core. These nanoparticles were used to
demonstrate effects of ISH in mice previously immunized with a licensed vaccine against Tetanus toxoid.
2. Materials and Methods
2.1. Mice, Ethical Statement
Six- to eight-week-old female wild-type (wt) C57bl/6NRj (Bl6) mice (Janvier, Le Genest-Saint-Isle,
France), as well as mice with transgenic B-cell receptors (BCR) specific for HIV-1 Env (PGT-121 mice [17],
in-house breeding, kindly provided by Dr. M. Nussenzweig, The Rockefeller University, New York,
NY, USA) were used in this study. Mice were accommodated in the animal facility of the Faculty of
Medicine, FAU (Erlangen, Germany), in accordance with the national law and were handled according
to instructions of the Federation of European Laboratory Animal Science Associations. All animal
experiments were approved by an external ethics committee of the North Rhine-Westphalian Ministry
for Nature, Environment and Consumer Protection (license AZ 84-02.04.2014. A191) and confirmed by
the Government of Lower Franconia (license 55.2-2532-2-96).
2.2. Plasmids and VLP Production
The plasmid encoding for BG505 NFL2P gp140 [18] was used for expression and purification of
stabilized Env trimers (see 2.3). We introduced recombinant transmembrane (TM) and cytoplasmic
(CD) domains of the surface protein G from the vesicular stomatitis virus (VSV-G; GenBank Accession
Number: GU177825.1) downstream of the sequence encoding for the soluble Env protein to elicit
pseudo-typed, membrane-bound Env trimers (BG505 NFL2P gp140-GTMCD). We further introduced
the nucleotide sequence ttcaacaacttcaccgttagcttctggctgcgcgttccgaaagtttctgcttcccacctggaa, that encodes
for the TT-derived peptide p30 (FNNFTVSFWLRVPKVSASHLE) into the Gag open reading frame
of the plasmid Hgpsyn [19] (Hgpsyn-TTp30) that contains the codon-optimized genetic information
for the HIV-1 structural precursor protein (Gag) and viral enzymes (Pol). The p30 sequence was
inserted between the p17 matrix protein and the p24 capsid protein. VLPs lacking Env (∆-VLP), VLPs
bearing BG505 NFL2P gp140-GTMCD Env trimers on the surface (Env-VLP) and Env-VLP with the
Gag-p30 fusion protein inside (Env-VLP-p30) were produced by co-transfection of 293T cells with
equal amounts of the corresponding plasmids and purified as described previously [20].
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2.3. Production and Analyses of HIV-1 Env Trimers
2.3.1. Production of HIV-1 Env Trimers
The HIV-1 subtype A envelope protein BG505 NFL2P gp140 (Env) was used as the primary antigen.
In brief, this antigen consists of three heterodimeric gp120-gp41ecto subunits and was stabilized for
the soluble, trimeric conformation by truncation of the transmembrane and cytoplasmic domains,
introduction of a flexible linker (2 x G4S) between the globular gp120 subunit and the gp41 ectodomain
as well as a point mutation at amino acid position 559 (I559P) [18]. Env trimers were produced by
transfection of 293F cells at a density of 1.0 × 106 cells per mL with the plasmid encoding for BG505
NFL2P gp140 (1 µg/mL DNA). Linear polyethylenimine (PEI, Polysciences Inc., Warrington, PA, USA)
was used as transfection reagent in a threefold excess compared to the mass of DNA. Cell culture medium
was changed 6 h after the transfection. The supernatant was harvested after three days, sterile-filtered
and run over a lectin affinity column (Agarose-bound Galanthus nivalis lectin, Vector Laboratories
Inc., Burlingame, CA, USA). Env trimers were eluted using 1M Methyl-α-D-mannopyranoside and
concentrated with a 10 kDa Amicon cutoff filter (Sigma-Aldrich, St. Louis, MO, USA). Between
the centrifugation steps, buffer changes were performed by refilling with DPBS without bivalent
cations (Thermo Fisher Scientific, Waltham, MA, USA). The final Env concentration was determined
by photometric measurement with a nanodrop device (Thermo Fisher Scientific, Waltham, MA,
USA). As a control, we introduced a stop codon downstream of the flexible linker and deleted the
nucleotide sequence for the gp41 ectodomain in order to produce gp120 monomers. These proteins
were purified in the same way as described above for the trimers. All purified proteins were analyzed
by NativePAGE and western blot (WB). For the UV-Vis spectroscopy (see 2.4.4) Env trimers were
labelled with AlexaFluor®-488 fluorescent dye using a protein labeling kit (Thermo Fisher Scientific,
Waltham, MA, USA) following the manufacturer’s instructions.
2.3.2. NativePAGE Analysis of HIV-1 Env Trimers
The native conformation of Env trimers and monomers was addressed using the NativePAGE
system (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s guidelines. In brief,
1 µg of each protein was mixed with G-250 additive and loaded onto a 4–16% Native Page Bis-Tris
gel. The proteins were separated according to their native size by gel electrophoresis. Afterwards,
excessive Coomassie stain was removed from the native gel by overnight fixation in 10% acetic acid
and 30% ethanol in ultra-pure H2O. Faint protein bands on the gel were then developed by staining
with silver nitrate using a Silver Stain Kit (Pierce Biotechnology Inc., Rockford, IL, USA).
2.3.3. Western Blot Analysis of HIV-1 Env Trimers
For the antigen-specific immunoblotting of purified Env, 1 µg of each soluble protein sample
or 300 ng Env on VLPs were mixed with house-made, reducing SDS sample buffer, boiled and then
loaded onto a 12% SDS gel. After gel electrophoresis, proteins were transferred onto a nitrocellulose
membrane which was subsequently blocked with 5% skimmed milk in DPBS supplemented with 0.1%
Tween20 (PBS-T). The blocked membranes were incubated with polyclonal goat anti-gp120 (Acris
Antibodies GmbH, Herford, Germany) and horseradish peroxidase-coupled secondary anti-goat IgG
antibody (Dianova, Hamburg, Germany) with multiple washing steps in between. The membranes
were finally developed with house-made ECL solution and protein bands were imaged using an
Advanced Fluorescence Imager (Intas, Göttingen, Germany).
2.4. Production of Calcium Phosphate Nanoparticles
2.4.1. Instruments
Dynamic light scattering (DLS) and zeta potential were measured with a Zetasizer Nano ZS
instrument (laser wavelength λ = 633 nm, Malvern Instruments, Malvern, UK) with the Smoluchowski
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approximation. Data obtained from Malvern software were used without further treatment; the
particle size results refer to the z-average. Scanning electron microscopy (SEM) was performed with an
ESEM Quanta 400 instrument (FEI Co., Hillsboro, OR, USA) and gold/palladium-sputtered samples.
Calcium concentrations were measured by atomic absorption spectroscopy (AAS) with an M-Series
AA spectrometer (Thermo Electron Corporation, Schwerte, Germany). UV-Vis absorption spectra were
measured with a DS-11 FX+ spectrophotometer (“Nanodrop”, DeNovix, Wilmington, DE, USA) and a
Cary 300 Bio spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). Ultracentrifugation
was done at 20 ◦C with a Sorvall WX Ultra Series centrifuge (Thermo Electron Corporation, Schwerte,
Germany). Freeze-drying (lyophilization) was carried out with a Christ Alpha 2-4 LSC instrument
(Martin Christ GmbH, Osterode am Harz, Germany). The endotoxin concentration was measured with
an Endosafe Nexgen-PTS handheld spectrophotometer (Charles River, Boston, MA USA). Ultrapure
water (Purelab, ELGA LabWater, Celle, Germany) was used for all preparations. All nanoparticles
were prepared and analyzed at room temperature.
2.4.2. Synthesis of Calcium Phosphate Nanoparticles
The CaP nanoparticle synthesis was performed according to our previously described method [21].
In brief, aqueous solutions of calcium lactate (18 mM, pH = 10, p.a., Sigma-Aldrich Corp., St. Louis,
MO, USA), diammonium hydrogen phosphate (10.8 mM, pH = 10, p.a., VWR Life-Sciences) and
branched polyethyleneimine (PEI, Mw = 25 kDa, Sigma-Aldrich Corp., St. Louis, MO, USA) were
simultaneously pumped at a volume ratio of 5:5:7 mL during one minute into a stirred vessel with
20 mL of ultrapure water. The dispersion was stirred for 20 min. and the CaP/PEI nanoparticle
dispersion was used immediately for the following steps. For the synthesis of adjuvant-containing
nanoparticles, 1 mL CaP/PEI nanoparticle dispersion was mixed with aqueous solutions of either 60 µL
p30 peptide (1 mg/mL) or 40 µL CpG (1 mg/mL) under stirring, followed by 30 min. stirring at room
temperature (RT). The adjuvant loading was determined by measuring the residual concentration in the
supernatant by UV microvolume spectroscopy (“nanodrop”). For further surface modifications a silica
shell was added to the nanoparticles. To this end, 1 mL of either CaP/PEI or of adjuvant-containing
nanoparticle dispersion was added to a mixture of 4 mL ethanol (Fisher Chemicals, Hampton, NH,
USA), 5 µL tetraethylorthosilicate (TEOS, Sigma-Aldrich Corp., St. Louis, MO, USA) and 10 µL
aqueous ammonia solution (7.8 wt.%) and stirred for 16 h. After this time, the nanoparticles were
isolated by ultracentrifugation (66,000× g, 30 min, 20 ◦C) and redispersed with 1 mL ultrapure
water followed by ultrasonication (UP50H, Hielscher, Teltow, Germany, sonotrode MS7m cycle
0.8, amplitude 70%, 4 s). Silica-terminated calcium phosphate nanoparticles (CaP/PEI/SiO2) were
obtained. To prepare the thiol-terminated calcium phosphate nanoparticles a surface modification
with (3-mercaptopropyl)trimethoxysilane (MPS, Sigma-Aldrich Corp., St. Louis, MO, USA) was
performed. For this, 1 mL of CaP/PEI/SiO2 nanoparticles was added to a mixture of 4 mL ethanol and
50 µL (3-mercaptopropyl)trimethoxysilane and stirred for 8 h. The nanoparticles were isolated by
ultracentrifugation (66,000× g, 30 min, 20 ◦C), redispersed with 1 mL H2O and ultrasonicated. After
this step, thiol-terminated calcium phosphate nanoparticles (CaP/PEI/SiO2-SH) were obtained.
2.4.3. Functionalization of CaP Nanoparticles with Env Trimers
The Env trimers (Mw = 140 kDa) were coupled to the nanoparticle surface via a
sulfo-SMCC cross-linker (sulfosuccinimidyl-trans-4-(N-maleimidomethyl)cyclohexane-1-carboxylate,
Merck, Darmstadt, Germany). One end of the linker reacts with the primary amines in Env and the
other end with the thiol groups on the nanoparticle surface. For this, 300 µL aqueous sulfo-SMCC
solution (1.78 mg/mL) were given to 600 µL Env in DPBS (1 mg/mL) and incubated for 2 h at 4 ◦C.
After incubation, the protein was purified from the unreacted cross-linker with a 3 kDa Amicon
ultracentrifuge filter (Merck, Darmstadt, Germany), following the manufacturer recommendations.
To attach the Env trimers to the nanoparticle surface, 330 µL activated protein (1 mg/mL) were given
to 4 mL CaP/PEI/SiO2-SH nanoparticle dispersion and incubated for 24 h at 4 ◦C. After this time,
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the particles were isolated by centrifugation at 21,000× g and 8 ◦C and washed once with 1 mL
H2O. Finally, the nanoparticles were redispersed in 4 mL H2O and ultrasonicated (UP50H, Hielscher,
sonotrode MS7m cycle 0.8, amplitude 70%, 4 s). The different syntheses were carried out with
sterile-filtered solutions.
2.4.4. CaP nanoparticle Characterization and Storage
For the final nanoparticle dispersion, an endotoxin quantification assay was performed with
an Endosafe Nexgen-PTS device. No endotoxin was detected in all synthesized nanoparticles
(<0.1 EU/mL). To calculate the number of nanoparticles per volume unit, the Ca2+ concentration
was measured by AAS and then tentatively expressed as the most common calcium phosphate, i.e.,
hydroxyapatite, Ca10(PO4)6(OH)2. The nanoparticle concentration in 1 mL dispersion is calculated
from the measured calcium phosphate concentration and the density of hydroxyapatite (3140 kg/m3)
assuming a complete spherical morphology. Additionally, the number of Env units on the nanoparticle
surface was determined by UV-Vis spectroscopy with an AlexaFluor®-488 labelled Env protein and
UV microvolume spectroscopy (“Nanodrop”) (see [22] for typical calculation steps to obtain these data).
For storage and transportation, the nanoparticle dispersion was lyophilized according to our previously
reported protocol [23]. 20 mg D-(+)-trehalose dihydrate (Sigma-Aldrich Corp., St. Louis, MO, USA)
were added to 1 mL of the nanoparticle dispersions as cryoprotectant followed by shock-freezing
with liquid nitrogen and lyophilization for 72 h at 0.31 mBar and −10 ◦C. Immediately before the
application, the nanoparticles were redispersed in 1 mL ultrapure water and gently sonicated with an
ultrasonication bath.
2.5. B-cell Activation In Vitro
B-cells from wt Bl6 mice or PGT-121 BCR-transgenic mice were isolated from the spleen by
magnetic cell separation (Miltenyi Biotec, Bergisch Gladbach, Germany, #130-090-862,). 2.0 × 105 cells
were incubated with different concentrations of Env-coupled nanoparticles in U-bottom 96-well plates.
As controls, we additionally incubated B cells with soluble Env trimers, with Env-VLP (0.2 µg of
Env/mL) and with 2 µg/mL of LPS (Sigma-Aldrich, Corp., St. Louis, MO, USA). After 18 h incubation
at 37 ◦C and 5% CO2, cells were stained with Fixable Viability Dye (Thermo Fisher Scientific, Waltham,
MA, USA) and with antibodies against the B-cell surface antigen CD19 (Thermo Fisher Scientific,
Waltham, MA, USA) and the early activation marker CD69 (Thermo Fisher Scientific, Waltham, MA,
USA). B-cell activation in living B-cells was subsequently measured on a benchtop flow cytometer
BD™ LSR II (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed with the FlowJo software (BD
Biosciences, Franklin Lakes, NJ, USA).
2.6. Analyses of In Vivo Induced Immune Responses
2.6.1. Immunization, Collection of Blood and Organ Samples
All immunizations were performed intramuscularly in both hind legs in Bl6 mice that were at the
age of 6–8 weeks by the time of the first injection. For the induction of intrastructural help, mice were
immunized on day 0 and day 28 with Tetanus toxoid vaccine (Tetanol®pur, GSK Vaccines GmbH,
Marburg, Germany) diluted 1:10 in sterile DPBS to induce CD4 T-cell responses against the TT peptide
p30 (ISH group) or with DPBS alone (control group). All mice were then boosted on day 56, day 84 and
day 112 with one of the following particle types: Env trimer-coupled CaP nanoparticles (Env-CaP);
Env-CaP with encapsulated p30 peptide (Env-CaP-p30); or Env-VLP-p30 with the membrane-bound
form of the Env trimer on the surface and the Gag-p30 fusion protein inside. To evaluate the influence
of encapsulated CpG as an adjuvant, mice were boosted thrice with Env-CaP-CpG particles in the
same immunization protocol as described above. The injection doses were normalized to 10 µg of Env
delivered with CaP nanoparticles and 300 ng of Env delivered with VLPs per mouse. To investigate
humoral immune responses against Env, blood samples were collected 2 weeks after each particle
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immunization. To investigate humoral immune responses against TT, blood samples were collected on
day 49. All blood samples were taken under isoflurane anesthesia from the retrobulbar venous plexus
with non-heparinized, single-use capillaries (minicaps®, Hirschmann, Eberstadt, Germany). Collected
blood samples were centrifuged for 5 min at 5000 rpm. The upper serum fractions were isolated and
stored at −20 ◦C. Mice were sacrificed on day 126 and spleens were isolated for further assessment of
the cellular immune response against both Env and p30.
2.6.2. Analyses of Humoral Immune Responses
Serum ELISAs to address the humoral immune response against Env were performed as described
previously [8]. Briefly, white opaque MaxiSorp 96-well plates (Greiner Bio One, Frickenhausen,
Germany) were coated with 100 ng Env trimer in coating buffer (0.1 M Na2CO3, 0.1 M NaHCO3 in
H2O, pH 9.6) per well at 4 ◦C overnight. After 1 h blocking with 5% skimmed milk (diluted in DPBS
containing 0.05% Tween-20), the wells were incubated with serum from immunized mice diluted 1:1000
in 2% skimmed milk for 1 h at RT. Plates were washed and then incubated for 1 h at RT with 1:4000
dilutions of HRP-coupled secondary antibodies specific for different murine IgG subtypes as well as
total IgG (Southern Biotech, Birmingham, AL, USA). After thorough washing, serum binding was
detected by addition of ECL solution and measurement of the relative light units per second (RLU/s)
with an Orion microplate luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany).
2.6.3. Analyses of Cellular Immune Responses
For the analysis of the cytokine profiles of both Env- and p30-specific CD4 T-cells after
immunizations, we performed in vitro intracellular cytokine staining (ICS) of CD4 T-cells for interferon
gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and interleukin-2 (IL-2), as well as cytokine
ELISA for IL-5. Isolated spleens were dissociated by using a gentleMACS™ Dissociator (Miltenyi
Biotech, Bergisch Gladbach, Germany) following the manufacturer’s guidelines. The cell suspensions
were run through 70 µm cell strainers. We removed erythrocytes by incubation with ACK lysis buffer
(150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA in H2O, pH 7.2) for 8 min at RT; the lysis reaction was
stopped by the addition of R10 medium (RPMI 1640, 10% FCS, 1% Penicillin-Streptomycin, 10 mM
HEPES, 2 mM L-glutamine, 50 µM 2-mercaptoethanol). The isolated splenocytes were washed twice by
centrifugation and resuspension in R10 and subsequently counted using a Countess Automated Cell
Counter (Thermo Fisher Scientific, Waltham, MA, USA ). Isolated splenocytes were seeded in 96-well
U-bottom plates (1.0 × 106 cells per well). For antigen-driven cytokine production by p30-specific
CD4 T-cells, splenocytes were re-stimulated with 5 µg/mL of p30 peptide. Since there is no identified
immunodominant MHC-II restricted Env peptides for Bl6 mice, we established a re-stimulation
protocol to induce Env-specific cellular responses. To this end, we purified PGT121 B-cells (see above)
and incubated them for 3 h at 37 ◦C with Env-VLPs containing 0.2 µg/mL Env or with the same amount
of ∆-VLP. Thereafter, the B-cells, that were supposed to take up the Env-VLP in a BCR-dependent
manner and subsequently present an array of different Env peptides to the CD4 T-cells, were washed
with R10 and added to splenocyte suspensions (1.5 × 105 PGT121 B-cells per well).
Intracellular Cytokine Staining
Antigen re-stimulated and unstimulated (control) splenocytes were incubated in the presence
of 2 µg/mL anti-mouse CD28 antibody and 3 µg/mL Brefeldin A (eBioscience, San Diego, CA, USA)
for 6 h at 37 ◦C and 5% CO2. After incubation, cells were washed with FACS buffer (1% FCS, 1 mM
EDTA in DPBS without bivalent cations) and stained with anti-mouse CD4 antibody (eBioscience,
San Diego, CA, USA) and Fixable Viability Dye (Thermo Fisher Scientific, Waltham, MA, USA). Then,
the cells were fixated with 2% paraformaldehyde in DPBS and subsequently permeabilized using
0.5% Saponin in FACS buffer and intracellularly stained with anti-mouse IL-2, IFN-γ and TNF-α
(eBioscience, San Diego, CA, USA). The cells were washed twice with permeabilization buffer and
twice with FACS buffer. The cytokine accumulation in the CD4 T-cells was then analyzed by flow
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cytometry. The background values of unstimulated cultures (∆-VLP for Env) were subtracted for each
individual mouse.
Cytokine ELISA
Antigen re-stimulated and control splenocytes were incubated in the presence of 2 µg/mL
anti-mouse CD28 antibody for 60 h at 37 ◦C and 5% CO2. The culture media were harvested and the
IL-5 cytokine secretion was analyzed using a Mouse IL-5 ELISA kit (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions. The background values of unstimulated cultures were
subtracted for each individual mouse.
2.7. Statistical Analysis
Statistical analyses were performed as indicated in the figure legends with the GraphPad Prism 7
software (Graphpad Software Inc., San Diego, CA, USA).
3. Results and Discussion
3.1. Production and Characterization of Soluble HIV-1 Env Trimers and Env-VLP-p30
For the coupling onto the surface of the CaP nanoparticles we needed faithful mimetics of the
HIV-1 Env spike. During the last decade, there were great efforts to create soluble Env trimers that
are stabilized in a closed pre-fusion conformation. This was achieved by truncation of the protein at
amino acid position 664 within the gp41 subunit as well as by the introduction of various stabilizing
mutations i.e., I559P [24].
In this study, we used an Env trimer that is derived from the membrane-embedded native form
(Figure 1A; left) of a subtype A HIV-1 isolate from an infected baby (BG505). In addition to the
modifications mentioned above, a flexible linker (2xG4S) was more recently introduced between the
gp120 subunit and the gp41 ectodomain to overcome the need for proper cleavage of the precursor
protein in order to receive stabilized well-folded proteins [18].
We expressed these Env trimers (BG505 NFL2P gp140) (Figure 1A, middle left) as well as
monomeric gp120 subunits (BG505 NFL2P gp120) (Figure 1A, middle right) in 293F cells and purified
them by Lectin affinity chromatography. The purified and concentrated proteins were analyzed on a
native gel followed by a silver staining. A prominent band at approximately 700 kDa represented the
globular native form of an Env trimer that is formed by three non-covalently assembled gp120-gp41ecto
(gp140) heterodimers (Figure 1B). Two minor bands showed a low percentage of gp140 dimers and
monomers. The purified gp120 resulted in two major bands on the native gel: a monomeric protein at
200 kDa and a gp120 dimer at 480 kDa that is formed by aberrant intermolecular di-sulfide bridges [25]
as well as a large aggregate fraction (Figure 1B). As expected, the expression of gp140 (but not of
gp120) results in the production of Env trimers, since the trimerization domain is located in the gp41
ectodomain and stabilized by the I559P mutation.
To compare intrastructural help for CaP nanoparticles side by side with that for HIV-1 VLPs,
we generated VLPs with a membrane-bound form of the stabilized Env trimer on the surface and
the TT-derived peptide p30 inside (Env-VLP-p30). In order to array stabilized BG505 NFL2P gp140
trimers on HIV-1 VLPs, the transmembrane and cytoplasmic domains of the vesicular stomatitis virus
G-protein (VSV-G) were fused to the open reading frame encoding Env. Figure 1C represents the BG505
NFL2P gp140-GTMCD expression construct and the corresponding protein (Figure 1A; right) has an
estimated size between 150 and 160 kDa. To produce HIV-1 VLPs that contain the p30 peptide of TT,
we inserted the coding sequence for the peptide in frame between the open-reading frame for matrix
and capsid of the HIV-1 structural Gag protein. Figure 1D represents the Hgpsyn-TTp30 construct.
Env-VLPs-p30 particles were produced by co-transfection of 293T cells with both the BG505 NFL2P
gp140-GTMCD and the Hgpsyn-TTp30 construct.
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The purified Env proteins as well as the produced Env-VLP-p30 particles were analyzed by Western
Blot under reducing conditions (Figure 1E). gp120 and gp140 were represented by prominent bands in
the respective sizes. The pseudotyped BG505 NFL2P gp140-GTMCD protein was approximately 150 to
160 kDa in size and, therefore, runs slightly higher than the soluble trimer (Figure 1E; upper panel).
In addition, three major Gag bands represent different states of the capsid maturation of the HIV-VLPs
(Figure 1E; lower panel).
These characterized Env trimers were further used for the coupling onto the surface of the
CaP nanoparticles.
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Env-VLP-p30 particles (BG505 NFL2P gp140-GTMCD; right). (B) Native PAGE of purified gp140 and 
gp120. Three gp140 molecules formed a globular trimer molecule represented by a major band at 700 
kDa. The gp120 subunit was expressed as monomeric or dimeric proteins, but did not form trimers. 
(C–D) Schematic overview of the plasmids used for Env-VLP-p30 production. (C) BG505 NFL2P 
gp140-GTMCD construct. Colors are matched to their respective protein domains in Figure 1A. (D) 
Hgpsyn-TTp30 construct: the nucleotide sequence for the p30 peptide was introduced between the 
HIV-1 p17 matrix protein and the spacer protein 1 followed by the capsid protein p24. (E) Reducing 
SDS-PAGE and Western Blot of purified soluble Env proteins and Env-VLP-p30. 
Figure 1. Production and characterization of soluble HIV-1 Env constructs and Env-p30-VLPs.
(A) Ov rview of different membrane-embedded and soluble Env constructs. The native BG505 gp160
(left), that is composed of three gp120 (grey) – gp41 (blue) heterodimers, has b en us d previously to
create a soluble stabilized recombinant trimer (BG505 NFL2P gp140; iddle left) by truncation at amino
a id 664 and introduction of both a poi t mutation (I559P) indicated with an asterisk (*) and flexible
linker (2xG4S). As a purification c ntr l, we produced a BG505 NFL2P gp120 monomer (middle right)
by truncation of the protein downstre m of the flexibl linker. A recombinant VSV-G trans embrane
and cytoplasmic domain (TM/CD; red) was introduced downstream of the gp41 ectodomain to create a
membrane- ound form of the tabilized trimer for production of Env-VLP-p30 particles (BG505 NFL2P
gp140-GTMCD; right). (B) Native PAGE of purified gp140 and gp120. Three gp140 molecules formed a
globular trimer molecule represented by a major band at 700 kDa. The gp120 subunit was ex ressed as
monomeric or dimeric proteins, but did not form tri ers. (C,D) Schematic overview of the plasmids
used for Env-VLP-p30 production. (C) BG505 NFL2P gp140-GTMCD construct. Colors are atched to
their respective protein domains in Figure 1A. (D) Hgpsyn-TTp30 construct: the nucleotide sequence
for the p30 peptide was intr duced between the HIV-1 p17 matrix protein and the spacer protein 1
followed by the capsid protein p24. (E) Reducing SDS-PAGE and West rn Blot of p rified soluble Env
proteins and Env-VLP-p30.
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3.2. Design, Production and Characterization of CaP Nanoparticles Functionalized with Soluble HIV-1
Env Trimers
Stable CaP nanoparticles were synthesized and the surface modified with soluble stabilized HIV-1
Env trimer proteins (Figure 1). The obtained nanoparticles had an average solid core diameter between
38-57 nm (as determined by SEM) (Figure 2) with a positively charged surface near +27 mV, due to
the stabilizing PEI polymer, and a hydrodynamic diameter between 300–400 nm. These parameters
make the nanoparticles suitable for cellular uptake [26]. The complete characterization data are shown
in Supplementary Table S1. For nanoparticles loaded with the T-helper peptide p30 or with CpG,
the load was absorbed onto the nanoparticle core before forming the external silica shell around it.
This coating provides protection to the internal loading but also permits a covalent surface modification
with Env [21].
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To determine the coupling efficiency of the Env proteins to the nanoparticles, an AlexaFluor®-488
labelled Env protein was used for the surface modification. After attaching this labelled protein,
the reaction yield was determined to 85% by UV-Vis spectroscopy. This factor was assumed to
calculate the concentration of Env after attaching the unlabelled protein under equivalent reaction
conditions. Additionally, a comparison for the Env concentration determined by nanodrop was
performed. The measured concentrations are shown in Supplementary Table S1. The Env concentration
determined by UV-Vis spectroscopy was used to calculate Env concentrations for all subsequent
nanoparticle preparations.
3.3. Antigen-Specific Activation of Naïve B-Cells with Env-CaP Nanoparticles In Vitro
Previously we demonstrated in vitro that CaP nanoparticles functionalized with a monovalent
model antigen activated naïve antigen-specific B-cells in a dose-dependent manner more efficiently
than the dissolved antigen alone [12]. In contrast to monomeric proteins, each stabilized soluble Env
trimer exposes up to 3 identical epitopes per molecule [29].
To investigate how the surface functionalization of CaP nanoparticle with stabilized HIV-1 Env
trimers influences the activation of naïve Env-specific B cells, we incubated B-cells from transgenic
mice that express the human PGT121 antibody [30] as B-cell receptors (Env B-cells) with Env-CaP
and soluble Env trimers (Figure 3A). Env-VLPs served as a positive control for BCR-specific B-cell
activation [31]. The stimulation with LPS showed the total polyclonal capability of the B-cells to be
activated [32]. Within a concentration range of 8 ng to 200 ng of Env per 1 mL of culture medium,
Env trimers arrayed on the CaP nanoparticle surface were able to activate Env-specific B cells more
efficiently in a dose-dependent manner than soluble trimers in the same concentrations (Figure 3A).
Incubation of wt B-cells in the presence of Env-CaP nanoparticles, soluble Env trimers or Env-VLPs
did not reveal Env-specific early B-cell activation (Figure 3B). The polyclonal activation of wt B-cells
with LPS (comparable to those of Env-specific B-cells) indicated the functional activity of the wt B-cells
(Figure 3) and, therefore, clearly demonstrates that all experimental Env preparations used were free of
polyclonal activators. Our results are consistent with the data reported by Ingale et al., who showed
that HIV-1 trimer-conjugated liposomes activated Env-specific B-cells better than soluble trimers [33].
Thus, the surface functionalization of CaP nanoparticles with soluble HIV-1 Env trimers improved
the dose-dependent activation of naïve Env-specific B-cells in vitro in comparison to soluble HIV-1
Env trimers alone.
3.4. Improvement of HIV-1 Env Antibody Responses by Intrastructural Help
To analyze the induction of anti-Env antibody responses in vivo, we applied Env-CaP nanoparticles
intramuscularly, as it was demonstrated to be the most appropriate way for the delivery of B- and
T-cell antigens with CaP nanoparticles into draining lymphoid organs [13]. In contrast to the
model antigen [13] in a highly reactive C3H mouse strain (as discussed in Reference [34]), Env-CaP
nanoparticles at a dose of 10 µg of Env protein per immunization induced poor anti-Env antibody
responses in Bl6 mice (Figure 4A, Env-CaP vs. naive).
Although Env-CaP nanoparticles are able to directly activate Env-specific B-cells in vitro (Figure 3),
the primary anti-Env antibody response in vivo is also dependent on CD4 T-cell help [35]. The low
magnitude of Env-specific IgG antibody responses induced with Env-CaP might be due to (i) a
suboptimal MHC-II restricted T-cell help [14] elicited by HIV-1 BG505 Env protein in Bl6 mice [36],
or (ii) suboptimal immunogenic capacities of Env-CaP (as discussed in [13]).
We have already demonstrated that the functionalization of CaP-HEL nanoparticles with the p30
peptide of TT (a universal T-helper epitope [14]) overcomes the lack of functionally active HEL-derived
CD4 T-cell epitopes in Bl6 mice [13]. The functionalization of Env-CaP nanoparticles with the p30
peptide increased the magnitude of the anti-Env IgG1 antibody response (Figure 4A, Env-CaP vs.
Env-CaP-p30), indicating an initially suboptimal MHC-II restricted T-cell help in mice immunized with
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Env-CaP. The anti-Env IgG2c antibody response, however, remained unaffected (Figure 4B, Env-CaP
vs. Env-CaP-p30).Nanomaterials 2019, 9, x FOR PEER REVIEW 11 of 17 
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Figure 3. Activation of naïve B-cells in vitro. Naïve B-cells were isolated from PGT121 (A) or wt (B)
mice and stimulated with Env trimers (8, 40 or 200 ng of Env/mL), Env-CaP nanoparticles (8, 40 or
200 ng of Env/mL), Env-VLPs (200 ng of Env/mL), or LPS (2 µg/mL). After 18h incubation, the cells
were stained with a viability dye and with anti-CD19 and anti-CD69 antibodies. The histograms
represent the expression of CD69 on the surface of viable CD19-positive B-cells. The numbers on the
histograms indicate the percentage of the gated CD69-positive cells and medians of the total CD69
fluorescence intensity.
To fu ther improve he Env-CaP-p30 induced anti-Env humoral immune responses, we recruited
pre-existing T-helper cells generated by the licensed Tetanol pur vaccine to provide ISH for Env-specific
B-cells. Mice previously vaccinated against Tetanus demonstrated significantly higher anti-Env
antibody responses after Env-CaP-p30 nanoparticle immunization, than the control animals injected
with DPBS instead of Tetanol pur (Figure 4A,B; Env-CaP-p30 vs. Env-CaP-p30 (ISH)). The in vitro
reactivation of p30-specific CD4 T-cells from the spleens of differently immunized mice revealed an
increase of potential heterologous T-cell help in the ISH group (Figure 4C–E). Intracellular cytokine
staining for the Th1 cytokines [37] IFN-γ (Figure 4C) and TNF-α (Figure 4D) showed a trend of being
more pronounced in the ISH group. The secretion of the Th2 cytokine [37] IL-5 after p30 reactivation
was significantly higher in the ISH group (Figure 4E). CD4 T-cells that produce either Th1 or Th2
cytokines support the generation of IgG2a (IgG2c in Bl6 mice) and IgG1 antibody subclasses in mice,
respectively [37,38]. The prominent Th2 cytokine profile of p30-specific CD4 T-cells is, therefore,
consistent with the predominant induction of the anti-Env IgG1 antibody subclass after immunizations
with Env-CaP-p30 nanoparticles (Figure 4A,B).
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Figure 4. Improvement of Env-specific IgG subtype responses after Env-CaP-p30 immunizations
by intrastructural help from Tetanus toxoid-specific T-helper cells. (A,B) IgG1 (A) and IgG2c (B)
Env-specific antibody responses were measured in sera from wt mice primed twice with DPBS or
Tetanol (ISH) and boosted 3 times with different CaP nanoparticles or Env-VLP-p30. (C,D) Percentages
of CD4 T-cells producing IFN-γ (C) and TNF-α (D) from differently immunized wt animals after in vitro
re-stimulation with p30 peptide were measured by intracellular cytokine staining. (E) p30-specific IL-5
cytokine secretion as determined by ELISA. The columns represent the mean values of six animals
± SEM. * p < 0.05; ** p < 0.001; *** p < 0.0005; **** p < 0.0001; one-way ANOVA with Tukey multiple
comparison post-hoc test.
Previously, we demonstrated ISH in mice immunized with Tetanol pur prior to administration of
HIV-1 derived VLPs containing different T helper epitopes of TT [8]. For direct comparison of the ISH
effects on the anti-Env antibody induction between the CaP nanoparticle platform and the HIV-1 VLP
system, we produced VLPs containing the p30 epitope of TT within Gag (Figure 1D) and presenting
stabilized BG505 Env trimers in a membrane-anchored form on their surface (Figure 1A,C). The VLP
antigen dosage was selected based on our previous studies [8,35] and was 0.3 µg of Env protein
per immunization. For the Env-VLP-p30 particles we observed intrastructural help (Figure 4A,B;
Env-VLP-p30 vs. Env-VLP-p30 (ISH)) in a magnitude comparable to the CaP nanoparticle platform
(Figure 4A,B; Env-VLP-p30 (ISH) vs. Env-CaP-p30 (ISH)).
Altogether, the incorporation of T-helper cell epitopes of non-HIV proteins into CaP nanoparticles
functionalized with HIV-1 Env trimers may allow the Env-specific B-cells to get T-cell help from
non-HIV specific CD4 T-cells via the ISH mechanism.
3.5. Distinct Effects of ISH and CpG-Adjuvants on the Induction of Env-Specific CD4 T-Cell Responses
Along with engaging the heterologous universal p30 T-helper epitope, functionalization of the
B-cell targeting CaP-nanoparticles with TLR-ligand significantly increased IgG antibody responses
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against a model antigen in mice [13]. The TLR9 ligand CpG demonstrated a number of advantages to
other TLR-ligands tested in the study (as discussed in Reference [13]). In addition, the CpG-based
adjuvant 1018 ISS [39] is already approved for clinical use.
To compare the improvement of antibody responses by CpG and ISH side-by-side, animals
previously immunized against Tetanus received either Env-CaP-p30 or Env-Cap-CpG nanoparticles.
Both Env-CaP-p30 and Env-Cap-CpG induced comparable total anti-Env IgG immune responses
(Figure 5A), although the anti-Env IgG subtype distribution varied between the groups (Figure 5B).
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Figure 5. Characterization of anti-Env immune responses after heterologous ISH and CpG adjuvantation.
(A) Env-specific antibody responses were measured in sera from wt mice primed twice with Tetanol
and boosted 3 times with either Env-CaP-p30 or Env-CaP-CpG. The columns represent the mean values
of six animals ± SEM. **** p < 0.0001; one-way ANOVA with Tukey multiple comparison post-hoc test.
(B) Env-specific IgG1/IgG2c ratios of individual mice. The columns represent the mean values of six
animals ± SEM. **** p < 0.0001; unpaired Student t-test. (C–E) Percentages of CD4 T-cells producing
IFN-γ (C), TNF-α (D) and IL-2 (E) from differently immunized wt animals after in vitro re-stimulation
with Env-VLPs were measured by intracellular cytokine staining. The columns represent the mean
values of six animals ± SEM. **** p < 0.0001; one-way ANOVA with Tukey multiple comparison
post-hoc test.
The efficacy of an HIV-1 vaccine, however, may not only depend on the strength of a protective
antibody response induced, but also on the magnitude of vaccine-induced immune mechanisms
increasing the susceptibility to infection. In particular, HIV-specific CD4 T-cell responses ay increase
the susceptibility to infection by expanding the number of activated CD4 T-cells as targets for the HIV-1
infection [1,6,7,40]. We therefore also compared CD4 T-cell responses in both vaccine groups.
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In contrast to Env-CaP-p30 nanoparticles that recruit and support heterologous (non-HIV-1 specific)
T-cell help (Figure 4), Env-CaP-CpG nanoparticles might induce increased Env-specific CD4 T-cell
response as a result of TLR9 ligation in dendritic cells [41,42]. Indeed, the percentage of Env-specific
CD4 T-cells in the spleens of immunized animals that can be reactivated in vitro after Env-VLP exposure
was significantly higher in the Env-CaP-CpG immunized animals (Figure 5B–D). Reactivation of
Env-specific CD4 T-cells producing Th1 pro-inflammatory [43] cytokines IFN-γ (Figure 5B) as well
as TNF-α (Figure 5C) and IL-2 (Figure 5E), a potent mitogen and growth factor for CD4 T-cells,
in mice from the Env-CaP-p30 (ISH) group was comparable to those in mice that received Env-CaP
or Env-CaP-p30 after DPBS injections. These results clearly demonstrated that ISH does not increase
expansion of Env-specific CD4 T-cells.
In non-human primate models of HIV/SIV infection, vaccinated animals with high numbers
of vaccine-induced IFN-γ secreting T-cells were more susceptible to acquisition of challenge virus
infection than poor T-cell responders [7,40], indicating that CpG functionalization of Env-CaP vaccines
may potentially enhance the susceptibility to acquisition of HIV-1 infection in vaccinees.
Thus, the incorporation of T-helper epitopes of heterologous (non-HIV) proteins in Env-CaP
nanoparticles was able to increase the magnitude of anti-Env specific IgG antibody responses by ISH
without significant induction of Env-specific IFN-γ producing CD4 T-helper cells. This suggests that
the ISH strategy for nanoparticle-based HIV-1 vaccines may allow to avoid induction of HIV-1 specific
CD4 T-cell responses suspected to enhance the susceptibility to HIV-1 infection.
4. Conclusions
We demonstrated that the incorporation of T-helper cell epitopes of non-HIV proteins into CaP
nanoparticles functionalized with HIV-1 Env trimers allows the Env-specific B-cells to receive T-cell
help from non-HIV specific CD4 T-cells via the ISH mechanism. In a mouse model, the Env-CaP-p30
nanoparticle-based vaccine was able to improve HIV-1 Env-specific antibody responses without
additional induction of HIV-specific CD4 T-cells suspected to increase the susceptibility to infection.
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